

Randomised trial of glutamine and selenium supplemented parenteral nutrition (PN) for critically ill patients

Submission date 23/02/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 24/02/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 16/05/2011	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Peter John Dawson Andrews

Contact details
Anaesthetics, Intensive Care & Pain Medicine
University of Edinburgh
Western General Hospital
Crewe Road
Edinburgh
United Kingdom
EH4 2XU

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Acronym

SIGNET Trial

Study objectives

This prospective, multicentre, pragmatic, placebo-controlled trial examines whether the inclusion of the amino acid glutamine or additional selenium, or the two together, improve the outcome of critically ill patients, when given as part of parenteral nutrition support. The main outcomes are infections, mortality, length of hospital and ICU stay. An economic evaluation is an integral component of this trial.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

2 x 2 factorial pragmatic multicentre double-blind randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Critically ill patients in intensive care

Interventions

Allocation will be to one of four groups for 7 days:

1. Standard parenteral nutrition (PN) bag, 12.5 g nitrogen, 2000 kcal daily, no glutamine or selenium
2. PN bag, 12.5 g nitrogen (including 20.2 g glutamine), 2000 kcal daily
3. Standard PN bag, 12.5 g nitrogen, 2000 kcal daily, 500 mcg selenium daily
4. PN bag, 12.5 g nitrogen (including 20.2 g glutamine), 2000 kcal daily, 500 mcg selenium daily

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Nitrogen, glutamine, selenium

Primary outcome(s)

1. Infections - counted as participants with new infection(s) in the first 14 days (based on the expected duration of effect and the length of follow-up in previous trials), using published

methods (infections based on Centers for Disease Control criteria)

2. Mortality - on ICU and overall at six months

3. Acute hospital and ICU length of stay

Key secondary outcome(s)

Days of antibiotic use; adverse events (see below); duration of PN use; alive, ventilator-free days as recommended by Rubenfield (26); patient quality of life measured by SF36 and EQ5D; costs to NHS, patients and carers/families; incremental cost per day in ICU saved and/or per quality adjusted life year (QALY). Data on all expected and unexpected adverse events, their severity and likelihood of causality by trial TPN are collected following a standard protocol, developed for the pilot (see enclosed PDF file). Once the trial office is informed of a Suspected Serious Adverse Reaction (SUSAR), it is reported to the MHRA within 7 days (none occurred during the pilot). Details of any SUSARs and Serious Suspected Adverse Reactions (SSARs) will also be provided in an annual safety report to the MHRA.

Completion date

30/04/2009

Eligibility

Key inclusion criteria

Any patient on intensive care unit (ICU) requiring PN (and expected to have at least half of daily nutritional requirements given by that route) will be eligible for entry into the trial.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. As the study is based in adult ICUs, occasional patients aged under 16 years of age will be excluded.

2. We also exclude pregnant women; and people with severe hepatic failure, severe metabolic acidosis or severe renal insufficiency based on contraindications to glutamine in the product information sheet.

Date of first enrolment

01/01/2004

Date of final enrolment

30/04/2009

Locations

Countries of recruitment

United Kingdom

Scotland

Study participating centre

Anaesthetics, Intensive Care & Pain Medicine

Edinburgh

United Kingdom

EH4 2XU

Sponsor information**Organisation**

NHS Lothian - University Hospitals Division (UK)

ROR

<https://ror.org/03q82t418>

Funder(s)**Funder type**

Government

Funder Name

Chief Scientist Office of the Scottish Executive Health Department

Funder Name

Fresenius Kabi

Funder Name

Oxford Nutrition

Funder Name

Medical Research Council (MRC) (UK) (G0401633)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/03/2011		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes